US Patent

US10456399 — Method for treating cancer patients with severe renal impairment

Method of Use · Assigned to Taiho Pharmaceutical Co Ltd · Expires 2037-02-03 · 11y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method for treating cancer in patients with severe renal impairment by orally administering a specific combination drug.

USPTO Abstract

A method for treating cancer in patients with creatinine clearance of 15 mL/min or more and less than 30 mL/min, including dividing a combination drug containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, in a dose of 30 to 50 mg/m 2 /day as FTD-equivalent, into two to four times a day, and orally administering it to the patient.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3657 —
U-3658 —

Patent Metadata

Patent number
US10456399
Jurisdiction
US
Classification
Method of Use
Expires
2037-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Taiho Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.